Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) ± topotecan in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A
Dar, S
Borok, R
Lisak, L
Andrews, C
Ekbal, M
Mazzoran, L
Zorat, F
Rifkin, S
Robin, E
Gregory, S
Venugopal, P
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Rush Canc Inst, Chicago, IL 60612 USA
[2] NW Community Hosp, Arlington Hts, IL USA
[3] Ingalls Mem Hosp, Harvey, IL USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1365
引用
收藏
页码：305A / 305A
页数：1
相关论文
共 50 条
  • [21] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [22] CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Silverman, L.
    Fenaux, P.
    Greenberg, P.
    Demakos, E.
    Santini, V.
    Seymour, J.
    Navada, S.
    Petrone, M.
    Snyder, B.
    Azarnia, N.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2015, 100 : 242 - 242
  • [23] Azacitidine (Vidaza®) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes (MDS).
    Lyons, R
    Cosgriff, T
    Modi, S
    Lintz, L
    Beach, CL
    Backstrom, JT
    BLOOD, 2005, 106 (11) : 707A - 707A
  • [24] Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement
    Latagliata, Roberto
    Niscola, Pasquale
    Oliva, Esther Natalie
    Riva, Marta
    Capodanno, Isabella
    Volpe, Antonio
    Pilo, Federica
    Barate, Claudia
    Campagna, Alessia
    Pelizzari, Anna Maria
    Poloni, Antonella
    Sarlo, Chiara
    Mansueto, Giovanna
    Piccioni, Anna Lina
    Rosati, Serena
    Carmosino, Ida
    Carbone, Antonella
    Tognazzi, Lucia
    Salutari, Prassede
    Mancini, Annalisa
    Cuffari, Patrizia
    Pennese, Elsa
    Fenu, Susanna
    Spiriti, Maria Antonietta Aloe
    Galimberti, Sara
    Molteni, Alfredo
    Balleari, Enrico
    Breccia, Massimo
    Foa, Robin
    Maurillo, Luca
    Finelli, Carlo
    BLOOD, 2019, 134
  • [25] Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)
    Montalban-Bravo, Guillermo
    Carcia-Manero, Guillermo
    Short, Nicholas J.
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Kadia, Tapan
    Borthakur, Gautam
    DiNardo, Courtney
    Miller, Darla
    Estrov, Zeev
    Pemmaraju, Naveen
    Daver, Naval
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [26] Response rates using international working group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine.
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    De Castro, CM
    Ellerton, J
    Knapp, KN
    Beach, CL
    Larson, RA
    BLOOD, 2005, 106 (11) : 709A - 709A
  • [27] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [28] Hematologic improvement in response to anti-tumor necrosis factor (TNF) therapy with Remicade® in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, LA
    Tahir, S
    Billmeier, JM
    Willmann, HS
    Bellak, DJ
    Alvi, MI
    Gezer, S
    Venugopal, P
    BLOOD, 2002, 100 (11) : 795A - 795A
  • [29] Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients
    Sebert, Marie
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Prebet, Thomas
    Cluzeau, Thomas
    Santini, Valeria
    Sanna, Alessandro
    Al Ali, Najla H.
    Hobson, Sean
    Eclache, Virginie
    List, Alan
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2013, 122 (21)
  • [30] Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (enbrel) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Allampallam, K
    Shetty, V
    Mundle, S
    Borok, R
    Lisak, L
    Andrews, C
    Ekbal, M
    Mazzoran, L
    Zorat, F
    Henderson, B
    Dangerfield, B
    Ansaarie, I
    Hussaini, S
    Broady-Robinson, L
    Venugopal, P
    BLOOD, 1999, 94 (10) : 171B - 171B
12345